Valvular & structural heart diseaseCohort study
Antiplatelet Therapy and All-Cause Mortality After Transcatheter Aortic Valve Replacement
- multicenter registry
Authors' conclusion
In a large real-world population of all comers undergoing TAVR, SAPT was associated with a significantly lower 6-month and 24-month all-cause mortality as compared with DAPT. (Transfusion Requirements in Transcatheter Aortic Valve Implantation [TRITAVI] Study; NCT03740425).
Study context
- Population
- Patients undergoing femoral transcatheter aortic valve replacement (TAVR) without indication to anticoagulation, recent percutaneous coronary intervention or procedural complications, discharged on single antiplatelet therapy (SAPT) or dual antiplatelet therapy (DAPT)remaining after exclusion of 4,557 of 10,071 registry patients
- Participants
- 5,514 patients
- Exposure
- SAPT vs DAPT after femoral TAVR
- SAPTn = 3,197reference
- DAPTn = 2,317
Main finding
As reported in the abstract
All-cause mortality · 6 months
log-rank P < 0.0001
Observational data: associations, not effects.
Further findings
Cardiovascular mortality · reduced with SAPT
P = 0.008
Noncardiovascular mortality · reduced with SAPT
P = 0.0001
Overall mortality · 24 months · lower with SAPT
log-rank P = 0.007
| Outcome | adjusted HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortality (Cox regression) · 6 months and 24 months · 6-month | 1.69 (1.20–2.37) | P = 0.002 | |
| All-cause mortality (Cox regression) · 6 months and 24 months · 24-month | 1.21 (1.01–1.46) | P = 0.04 | |
| 0.512Adjusted hazard ratio (log scale) |
Safety
Major bleeding · 6 months · lower with SAPT
log-rank P = 0.001
Original publication
Antiplatelet Therapy and All-Cause Mortality After Transcatheter Aortic Valve Replacement. JACC Adv. doi:10.1016/j.jacadv.2026.102772
Summarised from the published abstract; every number is checked against it